Lenvatinib + pembro is at least as active as other VEGF/IO combos. RR of 70% + PFS of 24 mnths (yes 24) are eye catching. OS of 0.66 in line with others. Low LFT AEs is important. Lenvatinib + evero has PFS but not OS signal. It’s role requires definition. ?post cabo/nivo #GU21
Overbevist at det å godkjenne COVID-19 vaksinene nå er riktig og glad for at utviklingen har gått så fort!
Støtter også veldig å flytte helsepersonell frem i prioriteringskøen og skal utvilsomt være en av de første som vaksineres selv når det er min tur! https://t.co/sCiBX6XQ32
Out now! Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019 published on @EUplatinum
👉 https://t.co/qRznL9n0rk
#apccc19#apccc21#prostatecancer @Els_Urology @urotoday
Den mest udiskutable fredsprisen på lenge deles ut, men avisene rydder forsidene for Farmen-Kjetil. Det får være måte på forsimpling av offentligheten, @vgnett og @dagbladet. Dette er flaut.
Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma | Business Wire https://t.co/TEngTvcxzE
18% had ADT + Doc as their SOC. adding RT to this had a similar HR to the effect of adding RT to ADT monotherapy (slightly bigger in fact). ADT/Doc/RT will be our SOC for this group in future in chemo fit pts